Nonsteroidal antiinflammatory drug intake according to the Assessment of SpondyloArthritis International Society Score in clinical trials evaluating tumor necrosis factor blockers: example of etanercept in advanced ankylosing spondylitis.

To evaluate the interest of the Assessment of SpondyloArthritis international Society (ASAS) nonsteroidal antiinflammatory drug (NSAID) score as a quality indicator and a potential outcome measure in clinical studies. We used data from patients with active, advanced, axial ankylosing spondylitis refractory to NSAIDs. The study design was a 12-week, randomized, placebo-controlled period followed by a 12-week open-label extension. The ASAS-NSAID score was collected during 3 periods of interest (i.e., the 12 weeks preceding baseline, the 12 weeks of the placebo-controlled trial, and the 12 weeks of the open-label trial). For the 82 enrolled patients, the mean ± SD ASAS-NSAID score at baseline was similar between the 2 groups: 93 ± 76 and 74 ± 54 in the etanercept and placebo groups, respectively. There was no significant change in the ASAS-NSAID score during the first part of the trial, as recommended by the protocol. There was a statistically significant decrease in the ASAS-NSAID score during the second part of the trial with a relevant effect size (-0.56) in the placebo to etanercept group. This study confirms the feasibility and simplicity of the ASAS-NSAID score and suggests that such a score be integrated in all studies in spondylarthritis either to check the quality of the observed data (i.e., intergroup baseline characteristics) or to evaluate the NSAID-sparing effect of other therapies.

Dougados M ，Braun J ，Szanto S ，Combe B ，Geher P ，Leblanc V ，Logeart I ... -  《-》

Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study.

Dougados M ，Wood E ，Combe B ，Schaeverbeke T ，Miceli-Richard C ，Berenbaum F ，Koppiker N ，Dubanchet A ，Logeart I ... -  《-》

Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.

Brandt J ，Khariouzov A ，Listing J ，Haibel H ，Sörensen H ，Grassnickel L ，Rudwaleit M ，Sieper J ，Braun J ... -  《ARTHRITIS AND RHEUMATISM》

Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks.

Davis JC ，van der Heijde DM ，Braun J ，Dougados M ，Cush J ，Clegg D ，Inman RD ，Kivitz A ，Zhou L ，Solinger A ，Tsuji W ... -  《-》

Discriminant Capacity of Clinical Efficacy and Nonsteroidal Antiinflammatory Drug-sparing Endpoints, Alone or in Combination, in Axial Spondyloarthritis.

Dougados M ，Wood E ，Gossec L ，Dubanchet A ，Logeart I ，van der Heijde D ... -  《-》